FDA approves Novartis’ Fabhalta in C3 glomerulopathy

Novartis’ Fabhalta notched another FDA approval, this time in adults with an ultra-rare kidney disease called C3 glomerulopathy. Fabhalta is the first drug approved specifically to treat C3 glomerulopathy, or C3G ...